Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Pharmacovigilance in Drug Therapy: Drug–Drug Interactions and Safety Evaluation, 2nd...
share announcement

Pharmacovigilance in Drug Therapy: Drug–Drug Interactions and Safety Evaluation, 2nd Edition

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 688

Special Issue Editor

Dr. Jacques Turgeon

E-Mail Website
Guest Editor
1.GalenusRx, Orlando, FL, USA
2. Faculty of Pharmacy, Université de Montréal, Montréal, QC H3C 3J7, Canada
Interests: drug metabolism; multi-drug interactions; clinical decision support systems; drug safety; drug-induced long QT syndrome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Medicines, whether they are small molecules, natural products, or biologics used to treat various diseases and conditions, inherently possess not only desired and expected effects but also, to a certain degree, unexpected and unwanted side-effects. The monitoring of the efficacy and toxicity of medicines within our armamentarium is at the heart of pharmacovigilance programs. Through pharmacovigilance programs, we can detect, assess, understand, and prevent adverse effects related to any medicine. Pharmacovigilance programs monitor medicine effectiveness, efficacy and safety not just under controlled product development conditions but also under real-world situations, i.e., in patients within their individualized environment and through exposure to different food products, with their various diseases, treated with multiple drugs, history of allergies, ethnicity, preferences, use of recreational drugs, alcohol and tobacco, etc. One of the drawbacks of pharmacovigilance programs is the necessary exposure of patients to medicine and their side-effects. Today, is it possible to develop new ways to assess medicine safety without exposing many patients to medicines? What are the tools and technologies available, such as simulation studies, artificial intelligence, virtual trials, pharmacogenomics, or real-world databases, that we could take advantage of and use to better predict drug safety? How could we better predict drug interactions, drug–food interactions, drug–disease interactions, drug–gene interactions, and drug–drug–gene interactions. The objective of this Special Issue, entitled “Pharmacovigilance in Drug Therapy: Drug–Drug Interactions and Safety Evaluation, 2nd Edition”, is to collect a series of publications that better inform the scientific community and the public about medication safety.

As the Guest Editor of this Special Issue of Pharmaceutics, I hope that you will accept my invitation to contribute an original paper.

Considering the success and great interest in papers submitted for the First Edition, we have launched a second edition to invite more interesting papers here.

Sincerely,

Dr. Jacques Turgeon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacovigilance
  • multi-drug interactions
  • clinical decision support systems
  • drug safety
  • drug side-effects
  • drug–drug interactions

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 933 KiB  
Article
Medication Errors in Psychiatric Hospitals: A Nationwide Real-World Evidence Study in Saudi Arabia
by Khalidah A. Alenzi, Mona Y. Alsheikh, Deemah S. Alsuhaibani, Yasser Alatawi and Thamir M. Alshammari
Pharmaceuticals 2024, 17(11), 1514; https://doi.org/10.3390/ph17111514 - 11 Nov 2024
Viewed by 482
Abstract
Background: Medication errors are among the most prevalent medical errors and result in significant morbidity and mortality. They pose a major threat to patient safety in psychiatric hospitals. However, the lack of a comprehensive investigation into the root causes of these errors [...] Read more.
Background: Medication errors are among the most prevalent medical errors and result in significant morbidity and mortality. They pose a major threat to patient safety in psychiatric hospitals. However, the lack of a comprehensive investigation into the root causes of these errors restricts the development of effective corrective measures. Objective: This study aimed to characterize the types of errors, determine the stages of the medication use process, and identify factors associated with errors occurring among government psychiatric hospitals in Saudi Arabia. Methods: This cross-sectional study was conducted from August 2019 to June 2020. All medication error reports submitted to the Ministry of Health General Administration of Pharmaceutical Care database from 18 government psychiatric hospitals in Saudi Arabia were assessed. The database is de-identified and contains information on all medication errors, including patient demographics, medication information, error information, causes of errors, and reporter information. Medication use was categorized as ordering/prescribing, transcribing, dispensing, administration, and monitoring. The present findings represent a descriptive analysis of the data using Statistical Analysis Software (SAS) version 9.4. Result: A total of 23,355 medication error reports were reported to the database during the study period. Among Saudi Arabian cities, Riyadh (n = 8972, 38.4%) had the highest medication error reporting rate, followed by Taif (n = 3705, 15.9%) and Jeddah (n = 2621, 11.2%). Most reported errors were frequently made by physicians (n = 20,284, 86.9%) and were primarily detected by pharmacists (n = 20,974, 89.8%). Approximately half of them (n = 13,150, 56.3%) were classified as “Category B” that occurred, but they did not reach patients. Most medication errors were reported in adults (n = 22,589, 96.7%) and male patients (n = 16,393, 70.2%). Most error reports were detected at the prescription stage (n = 16,481; 70.6%) during the medication-use process. Work overload of the staff (n = 2911, 12.8%) and drug labeling, packaging, and nomenclature (n = 2826, 12.1%) were the most common contributing factors associated with the reported errors. Olanzapine (n = 1650, 7.1%), omeprazole (n = 1350, 5.8%), and quetiapine (n = 1273, 5.5%) were the most common medications associated with medication errors. Conclusions: Preventable medication errors are typical in psychiatric hospitals and may result in severe consequences. Increased efforts are needed to control and minimize prescribing errors and improve reporting in Saudi Arabia. Full article
(This article belongs to the Special Issue Pharmacovigilance in Drug Therapy: Drug–Drug Interactions and Safety Evaluation, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop